Novel combinatorial approaches to enhancing oxygen transport to tissues

• US 20100144597A1
• Filed: 12/10/2009
• Published: 06/10/2010
• Est. Priority Date: 12/10/2008
• Status: Abandoned Application

• Current Assignee: Virginia Commonwealth University
• Original Assignee: Virginia Commonwealth University
• Inventors: Ward, Kevin R., Spiess, Bruce
• Application Number:
  US12/653,343
• Publication Number:
  US 20100144597A1
• Time in Patent Office: Days
• US Class Current: 514/13.400
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/025 carbocyclic
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 38/42 Haemoglobins; Myoglobins
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0026 Blood substitute; Oxygen transporting formulations; Plasma extender
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The subject application provides for a method for enhancing oxygen delivery to a tissue in a subject comprising administering to the subject a composition comprising two or more compounds selected from the group consisting of a hemoglobin based oxygen carrier, a nonhemoglobin based oxygen carrier, a rheologic modulator, a diffusion changing compound, a volume expander, and a vasomodulator. The subject application also provides for a method for enhancing oxygen delivery to a tissue in a subject comprising administering to the subject a composition comprising a perfluorocarbon and one or more compounds selected from the group consisting of a hemoglobin based oxygen carrier, a nonhemoglobin based oxygen carrier, a rheologic modulator, a diffusion changing compound, a volume expander, and a vasomodulator.

Claims

1. A method for enhancing oxygen delivery to a tissue in a subject comprising administering to the subject a composition comprising two or more compounds selected from the group consisting of a hemoglobin based oxygen carrier, a nonhemoglobin based oxygen carrier, a rheologic modulator, a diffusion changing compound, a volume expander, and a vasomodulator.

2. The method of claim 1, wherein the nonhemoglobin based oxygen carrier is a perfluorocarbon.

3. The method of claim 2, wherein the perfluorocarbon is perfluoro(tert-butylcyclohexane).

4. The method of claim 1, wherein the rheologic modulator is a drag-reducing polymer.

5. The method of claim 1, wherein the diffusion changing compound is crocetin.

6. The method of claim 1, wherein the volume expander is hypertonic saline solution.

7. The method of claim 1, wherein the vasomodulator is sildenafil.

8. The method of claim 1, wherein the subject is affected by a pathological condition.

9. The method of claim 8, wherein the pathological condition is a wound, a burn, traumatic shock, traumatic brain injury, organ ischemia, stroke, spinal cord injury, myocardial infarction, acute limb ischemia, mesenteric ischemia, isolated organ injury, congestive heart failure, adult respiratory distress syndrome, birth asphyxia, vasoocclusive crisis, hemorrhage, subarachnoid hemorrhage, systemic states of hypoxia, cardiac arrest, sepsis, decompression illness or acute respiratory disease (ARDS).

18. The method of claim 1, wherein the subject is a mammal.

19. The method of claim 18, wherein the mammal is a human.

10. A method for enhancing oxygen delivery to a tissue in a subject comprising administering to the subject a composition comprising a perfluorocarbon and one or more compounds selected from the group consisting of a hemoglobin based oxygen carrier, a nonhemoglobin based oxygen carrier, a rheologic modulator, a diffusion changing compound, a volume expander, and a vasomodulator.

11. The method of claim 10, wherein the perfluorocarbon is perfluoro(tert-butylcyclohexane).

12. The method of claim 10, wherein the rheologic modulator is a drag-reducing polymer.

13. The method of claim 10, wherein the diffusion changing compound is crocetin.

14. The method of claim 10, wherein the volume expander is hypertonic saline solution.

15. The method of claim 10, wherein the vasomodulator is sildenafil.

16. The method of claim 10, wherein the subject is affected by a pathological condition.

17. The method of claim 16, wherein the pathological condition is a wound, a burn, traumatic shock, traumatic brain injury, organ ischemia, stroke, spinal cord injury, myocardial infarction, acute limb ischemia, mesenteric ischemia, isolated organ injury, congestive heart failure, adult respiratory distress syndrome, birth asphyxia, vasoocclusive crisis, hemorrhage, subarachnoid hemorrhage, systemic states of hypoxia, cardiac arrest, sepsis, decompression illness or acute respiratory disease (ARDS).